Shield Therapeutics plc (LON:STX – Get Free Report)’s stock price rose 18.2% during trading on Tuesday . The stock traded as high as GBX 3.58 ($0.04) and last traded at GBX 3.46 ($0.04). Approximately 7,009,878 shares were traded during trading, an increase of 146% from the average daily volume of 2,846,169 shares. The stock had previously closed at GBX 2.93 ($0.04).
Shield Therapeutics Price Performance
The firm has a market capitalization of £29.36 million, a price-to-earnings ratio of -93.85 and a beta of 1.42. The company has a current ratio of 1.05, a quick ratio of 2.16 and a debt-to-equity ratio of 3,691.50. The business has a 50-day moving average price of GBX 2.74 and a two-hundred day moving average price of GBX 3.36.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.
Further Reading
- Five stocks we like better than Shield Therapeutics
- Quiet Period Expirations Explained
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Inflation Persists, But So Do Stock Opportunities: Rally On
- What is a buyback in stocks? A comprehensive guide for investors
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
